MDM2

Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma

J. N. Zhang, Yi, S. H., Zhang, X. H., Liu, X. Y., Mao, Q., Li, S. Q., Xiong, W. H., Qiu, Y. M., Chen, T., and Ge, J. W., Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma, vol. 11, pp. 3618-3628, 2012.

Epidemiological studies of the association of variants p53 Arg72Pro and MDM2 single-nucleotide polymorphism 309 (SNP309) with glioma risk have produced inconsistent results. The aim of the current study was to evaluate the association of these 2 variants with glioma susceptibility using a meta-analysis approach. For p53 Arg72Pro, 10 case-control studies including 2587 glioma patients and 4061 unrelated controls were identified.

Subscribe to MDM2